文献速递肝病消化道肿瘤与早癌

TGM2介导的组蛋白血清素化通过MYC信号通路促进肝细胞癌进展

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway.
PubMed 文献 · J Hepatol · 2025-01-07

本研究探讨转谷氨酰胺酶2(TGM2)介导的H3Q5ser修饰在肝细胞癌(HCC)进展中的作用。研究发现TGM2表达与较高甲胎蛋白水平、低分化和较晚BCLC分期正相关,抑制TGM2转谷氨酰胺酶活性可显著抑制HCC进展并与索拉非尼协同,且未引起明显骨髓抑制或组织损伤。

要点

  • TGM2表达与较高甲胎蛋白水平、低分化和较晚BCLC分期正相关。
  • 靶向TGM2转谷氨酰胺酶活性可显著抑制HCC进展,并与索拉非尼协同。
  • TGM2抑制剂未引起明显骨髓抑制或组织损伤。

核心结论

  • TGM2可作为预后生物标志物,靶向其转谷氨酰胺酶活性可能是抑制HCC进展的有效策略。

研究设计与样本

  • 采用腺相关病毒介导的肝脏特异性Tgm2或H3.3过表达模型验证H3Q5ser对HCC进展的影响。
  • 使用CUT&Tag和RNA测序探究潜在机制。
  • 使用HCC类器官、皮下异种移植模型和流体动力学尾静脉注射模型评估TGM2抑制剂的治疗效果。

主要发现

  • TGM2表达与较高甲胎蛋白水平、低分化和较晚BCLC分期正相关。
  • Tgm2缺失或抑制H3Q5ser显著抑制HCC进展。
  • CUT&Tag和RNA测序分析显示,TGM2抑制剂处理后下调基因富集于MYC通路。
  • 转录中介因子1β介导TGM2募集至MYC,促进MYC靶基因上的H3Q5ser修饰。
  • 靶向TGM2转谷氨酰胺酶活性显著抑制HCC进展,并在临床前模型中与索拉非尼治疗显示协同作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is an aggressive malignancy for which there are few effective treatment options. H3Q5ser, a serotonin-based histone modification mediated by transglutaminase 2 (TGM2), affects diverse biological processes, such as neurodevelopment. The role of TGM2-mediated H3Q5ser in HCC progression remains unclear. This study investigated the role of TGM2 in promoting HCC progression and evaluated its potential as a therapeutic target for HCC treatment. METHODS: Adeno-associated virus-mediated liver-specific overexpression models of Tgm2 or H3.3 were adopted to validate the effects of H3Q5ser on HCC progression. CUT&Tag and RNA sequencing was employed to investigate the underlying mechanisms. HCC organoids, subcutaneous xenograft models, and hydrodynamic tail vein injection models were used to evaluate the treatment efficiency of TGM2 inhibitors. RESULTS: TMG2 expression positively correlated with higher alpha-fetoprotein levels, poor differentiation, and a later BCLC stage. Tgm2 deficiency or H3Q5ser inhibition notably inhibited HCC progression. CUT&Tag and RNA sequencing analyses revealed that downregulated genes were enriched in the MYC pathway following treatment with TGM2 inhibitors. Furthermore, transcriptional intermediary factor 1 β mediated the recruitment of TGM2 to MYC, facilitating H3Q5ser modifications on MYC target genes. Finally, targeting the transglutaminase activity of TGM2 significantly suppressed HCC progression and showed synergy with sorafenib treatment in preclinical models. TGM2 inhibitors did not cause significant myelosuppression or tissue damage. CONCLUSIONS: TGM2 serves as a prognostic biomarker and targeting its transglutaminase activity may be an effective strategy for inhibiting HCC progression. IMPACT AND IMPLICATIONS: Transglutaminase 2 (TGM2)-mediated H3Q5ser modifications promote hepatocellular carcinoma (HCC) progression via MYC pathway signalling. Targeting the transglutaminase activity of TGM2 markedly inhibited HCC progression. TGM2 inhibitors did not induce significant myelosuppression or tissue damage. This preclinical study provides a theoretical basis to explore new strategies for HCC therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dong R, Wang T, Dong W, et al. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J Hepatol. 2025. PMID: 39788430. doi:10.1016/j.jhep.2024.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。